Inside AURA Biosciences: Routine RSU Sale, Clinical Advances, & Investor Insight
Insightful look at AURA Biosciences’ June 16 insider sale—understanding tax‑driven RSU vesting, clinical progress in nanotech oncology, and investor implications.
4 minutes to read






